PSMA2P2

Across TCGA pan-cancer cohorts, PSMA2P2 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated PSMA2P2 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PSMA2P2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PSMA2P2 expression acts as an unfavorable survival marker, although some lineages such as CESC and ESCA show a favorable association.

LIHC, THCA, and UCEC are the cancer types where PSMA2P2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	III,IV	0.111	0.356	<.001	81	view →
THCA	DFS	Quartile	II,III,IV	0.243	0.812	.005	60	view →
UCEC	OS	Median	II,III,IV	0.785	0.892	.003	44	view →
UCS	OS	Tertile	II,III,IV	0.290	0.606	.014	36	view →
UVM	DFS	Tertile	All	0.144	0.776	<.001	36	view →
KIRC	DFS	Tertile	IV	0.275	0.631	.003	24	view →
LUSC	DFS	Tertile	III,IV	0.286	0.823	.001	24	view →
READ	OS	Tertile	IV	0.541	0.925	.010	12	view →
CESC	DFS	Tertile	III,IV	0.896	0.651	.023	10	view →
BRCA	OS	Tertile	III,IV	0.744	0.858	.028	9	view →
MESO	DFS	Tertile	III,IV	0.219	0.392	.025	9	view →
PCPG	DFS	Tertile	All	0.644	0.867	.014	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

PSMA2P2–LIHC (DFS)

Open the LIHC breakdown →